Damora Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregist ered Sales of Equity Securities and Use of Proceeds.
On May 21, 2026, all 158.361 outstanding shares of Series A Preferred Stock were converted into 158,361 shares of Common Stock in accordance with their terms. The shares of Common Stock were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act, and no commission or other remuneration was paid or given for soliciting the conversion.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.